Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 Oct 2019 04:40 PM
RNS
Second Price Monitoring Extn
01 Oct 2019 04:35 PM
RNS
Price Monitoring Extension
30 Sep 2019 07:00 AM
RNS
Interim Results Announcement
18 Sep 2019 04:35 PM
RNS
Price Monitoring Extension
04 Jul 2019 07:00 AM
RNS
TR-1: notification of major holdings
02 Jul 2019 03:33 PM
RNS
TR-1: notification of major holdings
28 Jun 2019 07:00 AM
RNS
Update on Lupuzor
27 Jun 2019 01:38 PM
RNS
2019 Annual General Meeting
26 Jun 2019 07:00 AM
RNS
Subscription to raise £2.66 million
04 Jun 2019 07:00 AM
RNS
Notice of AGM and posting of Report & Accounts
24 May 2019 07:00 AM
RNS
FINAL RESULTS
07 May 2019 08:15 AM
RNS
Corporate Update - Replacement
07 May 2019 07:00 AM
RNS
Corporate Update
01 Apr 2019 07:00 AM
RNS
Update on Nucant Cancer Programme
14 Mar 2019 07:00 AM
RNS
Corporate Update
26 Feb 2019 07:00 AM
RNS
Technology review published-Nature Communications
31 Dec 2018 07:00 AM
RNS
Clinical Development Collaboration with Incanthera
21 Dec 2018 04:41 PM
RNS
Second Price Monitoring Extn
21 Dec 2018 04:36 PM
RNS
Price Monitoring Extension
20 Dec 2018 04:35 PM
RNS
Price Monitoring Extension
17 Dec 2018 07:00 AM
RNS
Appointment of Nominated Adviser
07 Dec 2018 07:00 AM
RNS
Update on Corporate Activities
29 Nov 2018 04:40 PM
RNS
Second Price Monitoring Extn
29 Nov 2018 04:35 PM
RNS
Price Monitoring Extension
28 Nov 2018 04:40 PM
RNS
Second Price Monitoring Extn
28 Nov 2018 04:35 PM
RNS
Price Monitoring Extension
23 Nov 2018 04:40 PM
RNS
Second Price Monitoring Extn
23 Nov 2018 04:35 PM
RNS
Price Monitoring Extension
21 Nov 2018 04:40 PM
RNS
Second Price Monitoring Extn
21 Nov 2018 04:35 PM
RNS
Price Monitoring Extension
07 Nov 2018 04:35 PM
RNS
Price Monitoring Extension
01 Nov 2018 01:38 PM
RNS
Nominated Adviser Status
26 Sep 2018 07:00 AM
RNS
Interim Results
19 Sep 2018 07:00 AM
RNS
Appointment of Joint Brokers
07 Sep 2018 07:00 AM
RNS
Corporate Update
10 Jul 2018 04:40 PM
RNS
Second Price Monitoring Extn
10 Jul 2018 04:35 PM
RNS
Price Monitoring Extension
28 Jun 2018 12:16 PM
RNS
Result of AGM
14 Jun 2018 07:00 AM
RNS
Results of CIDP Pre-Clinical Data
06 Jun 2018 07:00 AM
RNS
Notice of AGM & Posting of Annual Report
29 May 2018 07:00 AM
RNS
Update on Pivotal Phase III Trial of Lupuzor
29 May 2018 07:00 AM
RNS
Final Results
24 Apr 2018 11:59 AM
RNS
Holding(s) in Company
20 Apr 2018 08:24 AM
RNS
Holding(s) in Company
19 Apr 2018 08:05 AM
RNS
Holding(s) in Company
17 Apr 2018 07:00 AM
RNS
Topline results of Lupuzor Pivotal Phase III Trial
28 Mar 2018 07:00 AM
RNS
Appointment of Joint Broker
23 Mar 2018 07:00 AM
RNS
Lupuzor Pivotal Phase III Study Update
05 Mar 2018 04:13 PM
RNS
AIM Notice (17)
15 Feb 2018 07:00 AM
RNS
London Investor Evening

mmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

UK 100

Latest directors dealings